Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting NRIP1
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Topical, Intranasal, Vaginal, Intratumoral, Intraperitoneal, Parenteral, Implant
01
Overview
siRNA targeting NRIP1 (also referred to as siNRIP1) is an experimental, preclinical research tool that utilizes RNA interference (RNAi) technology to silence the expression of the Nuclear Receptor-Interacting Protein 1 (NRIP1, also known as RIP140) gene. NRIP1 is a transcriptional co-regulator involved in nuclear receptor signaling and various cellular processes. In preclinical studies, knockdown of NRIP1 using siRNA has been investigated across multiple indications, including breast cancer (where it induces apoptosis, inhibits cell growth, and suppresses tamoxifen resistance), metabolic diseases (such as obesity and type 2 diabetes), pre-eclampsia, non-small cell lung cancer, and psoriasis. It is primarily used as a laboratory reagent and is not currently being developed as a proprietary therapeutic by any pharmaceutical company.
- Other names
- siNRIP1siNRIP-1siNRIP 1siRNA targeting Nuclear Receptor-Interacting Protein 1siRNA targeting RIP140
02
Targets
NRIP1 (Nuclear receptor-interacting protein 1)
Beyond the preview
Go deeper on siRNA targeting NRIP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting NRIP1.